These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 34958428)

  • 21. Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC).
    Tan AC
    Thorac Cancer; 2020 Mar; 11(3):511-518. PubMed ID: 31989769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.
    Fumarola C; Bonelli MA; Petronini PG; Alfieri RR
    Biochem Pharmacol; 2014 Aug; 90(3):197-207. PubMed ID: 24863259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
    Burris HA
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):829-42. PubMed ID: 23377372
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
    Zheng R; Jiang H; Li J; Liu X; Xu H
    Curr Cancer Drug Targets; 2017; 17(4):376-385. PubMed ID: 28093061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors.
    Smit DJ; Cayrefourcq L; Haider MT; Hinz N; Pantel K; Alix-Panabières C; Jücker M
    Cells; 2020 Sep; 9(9):. PubMed ID: 32962206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
    Xia A; Li H; Li R; Lu L; Wu X
    Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.
    Bamodu OA; Chang HL; Ong JR; Lee WH; Yeh CT; Tsai JT
    Cells; 2020 Mar; 9(3):. PubMed ID: 32197467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PI3K/ Akt/ mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence.
    Narayanankutty A
    Curr Drug Targets; 2019; 20(12):1217-1226. PubMed ID: 31215384
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PI3K/AKT/mTOR Pathway Alterations Promote Malignant Progression and Xenograft Formation in Oligodendroglial Tumors.
    Tateishi K; Nakamura T; Juratli TA; Williams EA; Matsushita Y; Miyake S; Nishi M; Miller JJ; Tummala SS; Fink AL; Lelic N; Koerner MVA; Miyake Y; Sasame J; Fujimoto K; Tanaka T; Minamimoto R; Matsunaga S; Mukaihara S; Shuto T; Taguchi H; Udaka N; Murata H; Ryo A; Yamanaka S; Curry WT; Dias-Santagata D; Yamamoto T; Ichimura K; Batchelor TT; Chi AS; Iafrate AJ; Wakimoto H; Cahill DP
    Clin Cancer Res; 2019 Jul; 25(14):4375-4387. PubMed ID: 30975663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the PI3K/AKT/mTOR Pathway in Bladder Cancer.
    Sathe A; Nawroth R
    Methods Mol Biol; 2018; 1655():335-350. PubMed ID: 28889395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
    Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
    Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K/BMX/STAT3 signaling pathway.
    Peng J; Wang Q; Liu H; Ye M; Wu X; Guo L
    Tumour Biol; 2016 Sep; 37(9):11959-11971. PubMed ID: 27101199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
    Gadgeel SM; Wozniak A
    Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PI3K/Akt/mTOR signaling orchestrates the phenotypic transition and chemo-resistance of small cell lung cancer.
    Li X; Li C; Guo C; Zhao Q; Cao J; Huang HY; Yue M; Xue Y; Jin Y; Hu L; Ji H
    J Genet Genomics; 2021 Jul; 48(7):640-651. PubMed ID: 34167917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.
    Cardnell RJ; Feng Y; Diao L; Fan YH; Masrorpour F; Wang J; Shen Y; Mills GB; Minna JD; Heymach JV; Byers LA
    Clin Cancer Res; 2013 Nov; 19(22):6322-8. PubMed ID: 24077350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PI3K/AKT/mTOR pathway, hypoxia, and glucose metabolism: Potential targets to overcome radioresistance in small cell lung cancer.
    Deng H; Chen Y; Li P; Hang Q; Zhang P; Jin Y; Chen M
    Cancer Pathog Ther; 2023 Jan; 1(1):56-66. PubMed ID: 38328610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer.
    Maulik G; Madhiwala P; Brooks S; Ma PC; Kijima T; Tibaldi EV; Schaefer E; Parmar K; Salgia R
    J Cell Mol Med; 2002; 6(4):539-53. PubMed ID: 12611639
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of substituted 9-aminoacridine derivatives in small cell lung cancer.
    Ryan E; Blake AJ; Benoit A; David MF; Robert AK
    Invest New Drugs; 2013 Apr; 31(2):285-92. PubMed ID: 22821172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel multi-target tyrosine kinase inhibitor anlotinib combined with irinotecan has in-vitro anti-tumor activity against human small-cell lung cancer.
    Li H; Liu Y; Liu X; Zhao D; Liu J; Cheng Y
    Anticancer Drugs; 2020 Nov; 31(10):1057-1064. PubMed ID: 32694423
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PI3K/AKT/mTOR pathway is activated after imatinib secondary resistance in gastrointestinal stromal tumors (GISTs).
    Li J; Dang Y; Gao J; Li Y; Zou J; Shen L
    Med Oncol; 2015 Apr; 32(4):111. PubMed ID: 25757539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.